Juli 2022: Volgens het meest recente onderzoek van Emergen Research bereikte de wereldwijde markt voor CAR-T-celtherapie in 1.29 een omvang van 2021 miljard dollar en zal deze naar verwachting in de loop van de prognoseperiode een omzet-CAGR van 24.9 procent registreren. De toenemende incidentie van kanker over de hele wereld en het toenemende sterftecijfer als gevolg van kanker zullen naar verwachting de belangrijkste aanjagers zijn van de omzetgroei in de wereldwijde markt voor CAR-T-celtherapie in de loop van de prognoseperiode. De razendsnelle uitbreiding van activiteiten op het gebied van klinische studies, de wildgroei aan fusies en overnames en de aantrekkingskracht van beursintroducties zijn allemaal factoren die bijdragen aan de omzetgroei in de wereldwijde markt voor CAR T-celtherapie.
The primary objective of the report is to provide an overview of the market, including product scope, growth prospects, and potential risks. In-depth information about each participant in the global CAR T-celtherapie market, including that participant’s global standing, financial status, product launch, and business expansion plans, is included in the report. The participants in the market are concentrating their efforts on the creation of a variety of strategies, including partnerships, mergers and acquisitions, joint ventures, product launches, and investments in research and development.
According to the findings of the study, there are certain types of dangers and difficulties that can serve as an obstacle for a company. Granularity can be added to the overall research by performing an in-depth analysis of the CAR T-celtherapie market in the context of various aspects of the larger environment, such as the social, political, economic, and technological settings. In addition, the study generates real-time data on essential aspects such as sales, profits, gross margin, and growth prospects to demonstrate how going forward the company will see a significant upswing in its performance.
Aanvullende belangrijke bevindingen uit het rapport geven aan dat:
In 2021, het segment van de diffuse grote B-cel lymfoom was responsible for the majority of the rapid revenue share. A cancer of the lymphatic system, which is an essential component of the immune system, called diffuse large B-cell lymphoma has a rapid growth rate. It has an effect on the blood cells that generate antibodies, which are used to fight infections. In certain instances, DLBCL can be cured. The majority of patients suffering from DLBCL have a favourable response to initial treatments such as chemotherapy. In the case of some people, the illness either becomes resistant to treatment, which means that it no longer responds to it, or it relapses, which means that it returns after treatment has been completed. These patients may be candidates for treatment with chimere antigeenreceptor-T-celtherapie, which utilises the patient’s own immune cells in the fight against DLBCL. T-cells are taken out of the patient’s blood, modified in the laboratory with so-called chimeric antigen receptors that help in recognising and destroying cancer cells, and then reintroduced into the patient’s blood again. This process is repeated several times.
In 2021, the hospital segment was responsible for a fair amount of the total revenue. The CAR T-cell therapy will reprogramme the patient’s T-cells so that they will target the antigens produced by the tumour. CAR T-cell therapy has shown full remission rates of 80 to 90 percent in younger patients with B-cell acute lymphoblastic leukaemia, and it has shown a full remission rate of 40 percent in patients with symptomatic B-cell non-Hodgkin-lymfomen who have failed several prior lines of therapy. Both of these patient populations have B-cell acute lymphoblastic leukaemia.
De belangrijkste bedrijven die momenteel op de markt actief zijn, worden in dit rapport verder onderzocht, evenals hun bedrijfsprofielen, productportfolio's, uitbreidingsstrategieën en strategische allianties. Enkele voorbeelden van dit soort allianties zijn fusies en overnames, samenwerkingen en joint ventures. Daarnaast biedt het hoogtepunten over de prestaties en financiële positie van het bedrijf, evenals inzicht in het marktbereik en de wereldwijde positie van het bedrijf.
Bedrijven die zijn geprofileerd op de wereldwijde CAR T-Cell Therapy-markt:
Novartis AG, Pfizer Inc., CARsgen Therapeutics Co., Ltd, Daiichi Sankyo Company, Limited, Bristol-Myers Squibb Company, Astellas Pharma Inc., BioNTech SE, Biocad, F. Hoffmann-La Roche Ltd., en Eli Lilly and Company .
Lees meer over het wereldwijde CAR T-Cell Therapy-marktrapport op: https://www.emergenresearch.com/industry-report/car-t-cell-therapy-market
